Efekti tromesečnog kontinuiranog praćenja glukoze kod dece sa dijabetesom tipa 1 koja primaju više dnevnih doza insulinskih injekcija
Sažetak
Uvod/Cilj. Profesionalni sistem kontinuiranog monitoringa glikemije, iPro®2 (Medtronic), je dizajniran za nošenje u kombinaciji sa glukoznim senzorom, čija elektroda je insertovana u potkožno tkivo, do sedam dana, bez uvida u trenutni nivo glikemije. Nakon očitavanja podataka sa iPro®2 uređaja dobija se realna slika kretanja glikemije tokom perioda nošenja uređaja. Cilj ispitivanja bio je da se proveri da li informacije dobijene objektivnim merenjem putem profesionalnog kontinuiranog monitoringa glikemije doprinose poboljšanju metaboličke kontrole dece sa dijabetes melitusom tip 1 koji su na intenziviranom pen režimu insulinske terapije. Metode. Istraživanje je obuhvatilo 24 ispitanika (14 devojčica) uzrasta od 5 do 18 godina, prosečne starosti 12 ± 3.3 godina, u periodu jun-decembar 2016. godine na Klinici za dečije bolesti, Univerzitetski Klinički Centar, Banja Luka. Laboratorijski je izmeren glikozilirani hemoglobin (HbA1c) na početku ispitivanja, i nakon tri meseca kako bi se utvrdio efekat nošenja profesionalnog iPro®2 na metaboličku kontrolu, te nakon još tri meseca kako bi se proverili dugoročni efekti u odsustvu iPro®2 praćenja. Rezultati. Početni HbA1c bio je 7,78 ± 1,17% (min: 5,5%; max: 10%). Nakon tri meseca HbA1c pokazao je statistički značajno sniženje na 7,34% ± 0,84% (min: 5,60%; max: 8,90%). Na kontrolnom pregledu nakon šest meseci, bez upotrebe profesionalnog kontinuiranog monitoringa glikemije u međuvremenu, došlo je do značajnog porasta HbA1c na 7,68% ± 0,83% (min: 5,5%, max: 9,1%). Zaključak. Ova studija pokazuje da je nošenje profesionalnog kontinuiranog monitoringa glikemije sedam dana u mesecu, tri meseca u kontinuitetu, povezano sa određenim poboljšanjem metaboličke kontrole kod dece obolele od dijabetesa koja su na višednevnim insulinskim injekcijama, bez povećanja rizika od hipoglikemija.
Reference
Garg SK. The Future of Glucose Monitoring. Diabetes Tech-nol Ther 2016; 18 Suppl 2: S2iv-22.
Pickup JC, Freeman SC, Sutton AJ. Glycemic control in type 1 diabetes during real time continuous glucose monitoring com-paring with self-monitoring of blood glucose: a meta-analysis of randomized controlled trials using individual patient data. BMJ 2011; 343: d3805.
Battelino T, Conget B, Olsen B, Schütz-Fuhrmann I, Hommel E, Hoogma R. The use and efficacy of continuous glucose moni-toring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012; 55(12): 3155–62.
Battelino T, Philip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycaemia in type 1 diabetes. Diabetes Care 2011; 34(4): 795–800.
Garg SK. Role of Continuous Glucose Monitoring in Patients with diabetes using multiple daily insulin injections. Infusys-tems USA 2009; 6: 9–14.
Foster NC, Miller KM, Tamborlane WV, Bergenstal RM, Beck RW. Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care 2016; 39(6): e81–2.
Bachmann S, Hess M, Martin-Diener ,Denhaerynck K, Zumsteg U. Nocturnal hypoglycemia and physical activity in children with diabetes: new insights by continuous glucose monitoring and accelerometry. Diabetes Care 2016; 39(7): e95–6.
Bode WB, Battelino T. Continuous Glucose Monitoring in 2016. Diabetes Technol Ther 2017; 19(S1): S11–S18.
Zschornack E, Schmid C, Pleus S, Link M, Klötzer HM, Obermaier K, et al. Evaluation of the Performance of a Novel System for Continuous Glucose Monitoring. J Diabetes Sci Technol 2013; 7(4): 815–23.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, Block JM, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabe-tes Care 2009; 32(11): 1947–53.
Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. DIAMOND Study Group. Effect of Continu-ous Glucose Monitoring on Glycemic Control in adults with type 1 diabetes using insulin injections: The DIAMOND Ran-domized Clinical Trial. JAMA 2017; 317(4): 371–8.
Battelino T, Liabat S, Veeze HJ, Castaneda J, Arrieta A, Cohen O. Routine use of continuous glucose monitoring in 10501 peo-ple with diabetes mellitus. Diabet Med 2015; 32(12): 1568–74.
Bailey TS, Chang A, Christiansen M. Clinical accuracy of a con-tinuous glucose monitoring system with an advanced algo-rithm. J Diabetes Sci Technol 2015; 9(2): 209–14.
Christansen M, Bailey T, Watkins E, Liljenquist D, Price D, Na-kamura K, et al. A new-generation continuous glucose moni-toring system: improved accuracy and realability compared with a previous – generation system. Diabetes Technol Ther 2013; 15(10): 881–8.
American Diabetes Association. 11. Children and Adolescents. Diabetes Care 2016; 39 Suppl 1: S86–93.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring. Diabetes Technol Ther 2010; 12(9): 679-84.
Rewers MJ, Pillary K, de Beaufort C, Craig ME, Hanas R, Acerini CL, et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014; 15(Suppl 20): 102–14.
Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postpran-dial glucose control in type 1 diabetes: implications for inten-sive diabetes management in the continuous glucose monitor-ing era. Diabetes Care 2015; 38(6): 1008–15.
Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care 2015; 38(8): 1610–4.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Grou. Beck RW, Hirsh IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B,et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009; 32(8): 1378–83.
El Youssef J, Ward WK. Treatment Challenges for the Young Patient with Type 1 Diabetes. Diabetes Technol Ther 2015; 17(6): 367–9.
Telo GH, Volkening LK, Butler DA, Laffel LM. Salient Charac-teristics of Youth With Type 1 Diabetes Initiating Continuous Glucose Monitoring. Diabetes Technol Ther 2015; 17(6): 373–8.